查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1737055

標的蛋白質分解市場:分解設備類別，各適應症，各主要地區

Targeted Protein Degradation Market Distribution by Type of Degrader, Target Indication, Key Geographical Regions (North America, Europe, Asia-Pacific, and Rest of the World )
出版日期: | 出版商: Roots Analysis | 英文 450 Pages | 商品交期: 最快1-2個工作天內

價格

預計2035年，全球標靶蛋白降解市場規模將從目前的4.8億美元成長至69.4億美元，預測期間的複合年增長率為32%。

本市場區隔依據以下參數提供市場規模與機會分析：

依降解劑類型劃分

  • SERD
  • 專業折縫
  • 分子黏劑

各適應症

  • 乳癌
  • 多發性骨髓瘤

各主要地區

  • 北美(美國，加拿大)
  • 歐洲(英國，德國，法國，義大利，西班牙)
  • 亞太地區(中國，韓國，日本，印度，澳洲)
  • 其他地區(巴西，以色列)

標靶蛋白質降解 (TPD) 是一種新興的治療途徑，有望治療難治性疾病。傳統藥物（例如小分子抑制劑和單株抗體）僅針對不到 20% 的蛋白質組，而 TPD 則提供了一種新方法，可以接觸蛋白質組中大多數尚未開發的蛋白質。 TPD 使我們能夠透過控制有害蛋白質的數量而不是調節或抑制其功能來治療疾病。蛋白質數量的控制是透過稱為蛋白質降解劑的小分子藥物來實現的。 TPD 是雙功能小分子，可以募集 E3 泛素連接酶到目標蛋白質上，並介導泛素化以及隨後的蛋白酶體蛋白質降解。

Targeted Protein Degradation Market-IMG1

與傳統的藥物研發策略相比，透過小分子進行選擇性TPD（標靶蛋白降解）具有諸多優勢：其主要優勢之一是可利用細胞機制的多層選擇性快速驗證標靶特異性。此外，由於TPD降解分子不會被破壞，因此可以破壞大量有害蛋白質的拷貝，從而減少全身性藥物暴露。此外，透過抑制蛋白質的功能，可以抑制靶向蛋白的表達增加。值得注意的是，單一蛋白質降解劑可能能夠透過蛋白酶體降解標靶蛋白去除多種致病蛋白質。由於上述優勢以及技術的持續進步，預計靶向蛋白降解市場在預測期內將實現顯著增長。

標靶蛋白降解市場：關鍵洞察

本報告深入探討了標靶蛋白降解市場的現狀，並識別了產業內的潛在成長機會。報告的主要發現包括：

  • 超過 285 種標靶蛋白降解療法已獲批准或處於不同的研發階段。市場格局呈現成熟企業和新進業者並存的格局。
  • 正在評估的標靶蛋白降解劑中，超過 20% 為分子黏附劑，其中超過 70% 用於治療癌症疾病。
  • 超過 35% 的技術專注於 PROTAC 的開發，其中 38% 能夠使用 CADD 分析識別標靶。
Targeted Protein Degradation Market-IMG2
  • 目前，約有 85 種創新的標靶蛋白質降解技術可用於開發穩定且有效的降解劑。
  • 目前，約有 250 項臨床試驗（約 63,000 名患者入組）正在進行中，旨在研究標靶蛋白質降解療法在不同地區治療各種疾病的效果。
  • 自 2019 年以來，美國國立衛生研究院 (NIH) 已撥款超過 1.65 億美元，其中約 80% 的撥款支持期為 1-4 年。
Targeted Protein Degradation Market-IMG3
  • 過去五年，多篇論文已發表於各類高影響力期刊，這些論文在亞太地區引起了越來越多的關注。
  • 為了保護該領域產生的智慧財產權，工業和非工業參與者已就標靶蛋白質降解劑及相關技術申請了超過985項專利。
  • 近年來，各利益相關者之間建立了廣泛的合作夥伴關係，這也反映了各方日益增長的興趣，其中25%的交易專注於新型蛋白質降解劑的研發。
  • 一些投資者已經意識到靶向蛋白質降解領域的機遇，並在過去六年中在多輪融資中投資了約 135 億美元。
  • 由於蛋白質降解劑能夠選擇性降解無法治療的標靶，標靶蛋白質降解市場預計未來十年將以每年 32% 的速度成長。
Targeted Protein Degradation Market-IMG4
  • 市場估值和預測預計將分佈在不同國家，特別是美國、法國、西班牙、英國和中國。

標靶蛋白降解市場：關鍵細分市場

根據降解劑類型，市場細分為SERD、PROTAC和分子黏合劑。目前，由於用於治療轉移性乳癌的口服SERD藥物Elacestrant (ORSERDU)獲得批准，SERD細分市場在標靶蛋白降解市場中佔最大佔有率。此外，PROTAC細分市場預計在預測期內將以更快的速度成長。

根據標靶適應症，市場細分為乳癌和多發性骨髓瘤。目前，乳癌在標靶蛋白降解市場中佔比最高。由於乳癌發生率不斷上升，佔新診斷病例的12.5%以上，這一趨勢很可能保持不變。此外，在預測期內，乳癌細分市場的標靶蛋白降解市場可能以相對較高的複合年增長率成長。

依主要地區劃分，市場分為北美、歐洲、亞太地區及世界其他地區。目前，北美在靶向蛋白降解市場佔據主導地位，佔據最大的收入佔有率。此外，預計未來幾年亞太地區市場將以更高的複合年增長率成長。

本報告提供全球標的蛋白質分解市場相關調查，提供市場概要，以及分解設備類別，各適應症，各主要地區的趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 序文

第1章 1.市場概要

第2章 調查手法

第3章 經濟以及其他的計劃特有的考慮事項

第4章 摘要整理

第5章 簡介

  • 章概要
  • 標的蛋白質分解概要
  • 標的蛋白質分解途徑
  • 蛋白質分解劑的種類
  • 對象治療領域
  • 標的蛋白質分解伴隨的優點與課題
  • 未來展望

第6章 市場形勢:標的蛋白質分解療法

  • 章概要
  • 標的蛋白質分解療法:市場形勢
  • 標的蛋白質分解療法的開發商:市場形勢

第7章 市場形勢:標的蛋白質分解技術

  • 章概要
  • 標的蛋白質分解技術:市場形勢

第8章 企業簡介

  • 章概要
  • 主要加入企業的詳細內容簡介
    • Arvinas
    • Bristol-Myers Squibb
    • C4 Therapeutics
    • Loxo Oncology
    • Olema Oncology
    • Radius Health
    • AstraZeneca
    • Roche
  • 其他的企業的簡介
    • BeiGene
    • InnoCare Pharma
    • Kangpu Biopharmaceuticals
    • Kintor Pharmaceuticals
    • Medivir
    • Monte Rosa Therapeutics
    • Ranok Therapeutics
    • Sanofi
    • Zentalis Pharmaceuticals
    • Eisai Therapeutics

第9章 臨床試驗的分析

  • 章概要
  • 範圍與調查手法
  • 標的蛋白質分解:臨床試驗分析

第10章 津貼分析

  • 章概要
  • 範圍與調查手法
  • 標的蛋白質分解:津貼分析

第11章 專利分析

  • 章概要
  • 範圍與調查手法
  • 標的蛋白質分解:專利分析
  • 專利基準分析
  • 專利評估
  • 引用數前幾名的專利

第12章 出版物的分析

第13章 夥伴關係和合作

第14章 資金籌措與投資

第15章 市場影響分析:促進因素，阻礙因素，機會，課題

第16章 全球標的蛋白質分解市場

  • 章概要
  • 主要的前提與調查手法
  • 全球標的蛋白質分解市場，預測(到2035年)
  • 主要的市場區隔

第17章 標的蛋白質分解市場(分解設備類別)

第18章 標的蛋白質分解市場(各標的適應症)

第19章 標的蛋白質分解市場(各主要地區)

第20章 標的蛋白質分解市場，醫藥品的銷售額預測

  • 章概要
  • 關鍵假設與研究方法
  • 商業化標靶蛋白降解市場：銷售預測
  • III期標靶蛋白降解市場：銷售預測
  • 資料三角測量與驗證

第21章 全球標的蛋白質分解技術市場

第22章 執行洞察

第23章 結論

第24章 附錄1:表格形式資料

第25章 附錄2:企業·團體一覽

第26章 附錄3:資金籌措和投資的清單

Product Code: RA100259A

TARGETED PROTEIN DEGRADATION MARKET: OVERVIEW

As per Roots Analysis, the global targeted protein degradation market is estimated to grow from USD 0.48 billion in the current year to USD 6.94 billion by 2035, at a CAGR of 32% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Degrader

  • SERD
  • PROTAC
  • Molecular Glue

Target Indication

  • Breast Cancer
  • Multiple Myeloma

Key Geographical Regions

  • North America (US and Canada)
  • Europe (UK, Germany, France, Italy and Spain)
  • Asia-Pacific (China, South Korea, Japan, India and Australia)
  • Rest of the World (Brazil and Israel)

TARGETED PROTEIN DEGRADATION MARKET: GROWTH AND TRENDS

Targeted protein degradation (TPD) is an emerging therapeutic modality that has the potential to enable the treatment of difficult-to-treat diseases. While conventional medicines, such as small molecule inhibitors and monoclonal antibodies, target less than 20% of the proteome, TPD provides a novel approach to access the vast majority of unexplored proteins within the proteome. Through TPD, a disease can be addressed by controlling the amount of harmful protein rather than trying to modulate or inhibit its function. The control of protein levels is accomplished with a small molecule drug, called a protein degrader. TPD is a bifunctional small molecule that recruits E3 ubiquitin ligases to the protein of interest and mediates its ubiquitination and subsequent proteolysis by the proteasome.

Targeted Protein Degradation Market - IMG1

Small molecule-mediated selective TPD has several advantages over traditional drug discovery strategies. One of the primary advantages is the high degree of target specificity that can be rapidly validated by leveraging the multiple layers of selectivity in the cellular machinery. Moreover, owing to the fact that the TPD degrader molecules cannot be destroyed, they can cause the destruction of many copies of harmful proteins and reduce systemic drug exposure. In addition, it can counteract increased target protein expression by inhibiting the protein function. It is worth noting that a single protein degrader has the ability to potentially eliminate multiple disease-causing proteins through proteasome degradation of the target protein. Owing to the above-mentioned advantages and the ongoing pace of technological advancements, the targeted protein degradation market is poised to experience noteworthy growth during the forecast period.

TARGETED PROTEIN DEGRADATION MARKET: KEY INSIGHTS

The report delves into the current state of the targeted protein degradation market and identifies potential growth opportunities within industry. Some key findings from the report include:

  • 285+ targeted protein degradation therapies are either approved or being investigated in different stages of development; the market landscape features the presence of both established players and new entrants.
  • Over 20% of the targeted protein degraders being evaluated are molecular glues; of these, more than 70% are intended for the treatment of oncological disorders.
  • Over 35% of the technologies are focused on developing PROTACs; of these, 38% have the capability to identify the targets utilizing CADD analysis.
Targeted Protein Degradation Market - IMG2
  • At present, around 85 innovative targeted protein degradation technologies are available for developing stable and efficacious degraders; further, majority of the technology providers are start-ups / small businesses.
  • Around 250 clinical trials (with around 63,000 enrolled patients) are currently underway to investigate targeted protein degradation therapies intended for treatment of various diseases, across different geographies.
  • Since 2019, grants worth over USD 165 million have been awarded by NIH; ~80% of these grants were awarded for a support period of 1-4 years.
Targeted Protein Degradation Market - IMG3
  • In the last five years, several articles have been published in various high-impact journals; such publications have garnered more interest in the Asia-Pacific region.
  • More than 985 patents have been filed for targeted protein degraders and related technologies by industry and non-industry players, to protect intellectual property generated within this field.
  • The rising interest is reflected in the wide array of partnerships established between various stakeholders in the recent past; 25% of the deals were focused on research and development of novel protein degraders.
  • Several investors have realized the opportunity within the domain of targeted protein degradation and invested around USD 13.5 billion across various funding rounds in the past six years.
  • Owing to the protein degraders ability to degrade the undruggable targets selectively, the targeted protein degradation therapies market is anticipated to witness an annualized growth of 32% over the next decade.
Targeted Protein Degradation Market - IMG4
  • The estimated market opportunity is projected to be distributed across different countries, especially in the US, France, Spain, the UK and China.

TARGETED PROTEIN DEGRADATION MARKET: KEY SEGMENTS

SERD Segment Occupies the Largest Share of the Targeted Protein Degradation Market

Based on the type of degrader, the market is segmented into SERD, PROTAC and molecular glue. At present, the SERD segment holds the maximum share of the targeted protein degradation market owing to the approval of elacestrant (ORSERDU), an oral SERD for metastatic breast cancer. Additionally, the PROTAC segment is likely to grow at a faster pace during the forecasted period.

By Target Indication, Breast Cancer is the Fastest Growing Segment of the Global Targeted Protein Degradation Market

Based on the target indication, the market is segmented into breast cancer and multiple myeloma. Currently, the breast cancer segment captures the highest proportion of the targeted protein degradation market. This trend is likely to remain the same in the future owing to the increasing prevalence of breast cancer, with over 12.5% of all newly diagnosed cases. Further, targeted protein degradation market for the breast cancer segment is likely to grow at a relatively higher CAGR during the forecast period.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World. Currently, North America dominates the targeted protein degradation market and accounts for the largest revenue share. Further, the market in Asia-Pacific is expected to grow at a higher CAGR in the coming years.

Example Players in the Targeted Protein Degradation Market

  • Arvinas
  • AstraZeneca
  • BeiGene
  • Bristol-Myers Squibb
  • C4 Therapeutics
  • Eisai Therapeutics
  • InnoCare Pharma
  • Kangpu Biopharmaceuticals
  • Kintor Pharmaceutical
  • Loxo Oncology
  • Medivir
  • Monte Rosa Therapeutics
  • Olema Oncology
  • Radius Health
  • Ranok Therapeutics
  • Roche
  • Sanofi
  • Zentalis Pharmaceuticals

TARGETED PROTEIN DEGRADATION MARKET: RESEARCH COVERAGE

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the targeted protein degradation market, focusing on key market segments, including [A] type of degrader, [B] target indication, and [C] key geographical regions.
  • Targeted Protein Degradation Therapies Market Landscape: A comprehensive evaluation of the companies engaged in targeted protein degradation therapies market, based on several relevant parameters, such as [A] stage of development, [B] type of degrader, [C] biological target, [D] target enzyme, [E] target indication and [F] therapeutic area. Additionally, a comprehensive evaluation of the targeted protein degradation therapy developers, based on several relevant parameters, such as [G] year of establishment, [H] company size, [I] location of headquarters and [J] most active players.
  • Targeted Protein Degradation Technologies Market Landscape: A comprehensive evaluation of the companies engaged in targeted protein degradation technologies market, based on several relevant parameters, such as [A] type of degrader developed, [B] protein degradation pathway, [C] site of degraded protein, [D] therapeutic area, [E] discovery step supported and [F] availability of computational modeling ability. Additionally, a comprehensive evaluation of the companies offering targeted protein degradation technologies, based on several relevant parameters, such as [G] year of establishment, [H] company size and [I] location of headquarters.
  • Company Profiles: In-depth profiles of key companies engaged in the targeted protein degradation market, focusing on [A] overview of the company, [B] financial information (if available), [C] technology portfolio, [D] pipeline overview and [E] recent developments and an [F] informed future outlook.
  • Clinical Trial Analysis: An insightful analysis of clinical trials related to targeted protein degradation, based on several parameters, such as [A] trial registration year, [B] number of patients enrolled, [C] trial phase, [D] trial status, [E] patient gender, [F] target indication, [G] study design, [H] most active sponsor / collaborator and [I] geography.
  • Grants Analysis: A comprehensive assessment of grants that have been awarded to research institutes in the targeted protein degradation domain, based on various relevant parameters, such as [A] year of grant award, [B] amount awarded, [C] funding institute centers, [D] support period, [E] type of grant application, [F] purpose of grant award, [G] activity code, [H] study section involved, [I] popular NIH departments, [J] prominent program officers, [k] popular recipient organizations and [L] distribution of popular recipient organizations by states in the US.
  • Patent Analysis: An in-depth analysis of patents filed / granted till date in the targeted protein degradation domain, based on various relevant parameters, such as [A] type of patent, [B] patent application year, [C] patent publication year, [D] patent jurisdiction, [E] CPC symbols, [F] type of applicant, [G] individual patent assignees, [H] patent age, [I] patent benchmarking, and [J] patent valuation analysis.
  • Publication Analysis: An insightful analysis of peer-reviewed scientific articles related to research on targeted protein degradation, based on various relevant parameters, such as [A] year of publication, [B] type of publication, [C] key journal, [D] most active publisher, [E] most active copyright holder, [F] most popular keywords, [G] therapeutic area and [H] key geographical regions.
  • Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in the targeted protein degradation market, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] type of partner, [D] type of degrader, [E] most active players and [F] geographical distribution of the partnership activity.
  • Funding and Investments: An in-depth analysis of the fundings raised by targeted protein degradation companies, based on relevant parameters, such as [A] year-wise trend of funding instances, [B] amount invested, [C] type of funding, [D] geographical analysis, [E] leading players and [F] leading investors.
  • Market Impact Analysis: A thorough analysis of various factors, such as drivers, restraints, opportunities, and existing challenges that are likely to impact market growth.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What factors are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

  • Complimentary PPT Insights Packs
  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

1.1. Market Overview

  • 1.2. Market Share Insights
  • 1.3. Key Market Insights
  • 1.4. Report Coverage
  • 1.5. Frequently Asked Questions
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
  • 2.3. Project Methodology
  • 2.4. Forecast Methodology
  • 2.5. Robust Quality Control
  • 2.6. Key Market Segmentations
  • 2.7. Key Considerations
    • 2.7.1. Demographics
    • 2.7.2. Economic Factors
    • 2.7.3. Government Regulations
    • 2.7.4. Supply Chain
    • 2.7.5. COVID Impact
    • 2.7.6. Market Access
    • 2.7.7. Healthcare Policies
    • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1. Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Future Estimates
    • 3.2.2. Currency Coverage and Foreign Exchange Rate
      • 3.2.2.1. Major Currencies Affecting the Market
      • 3.2.2.2. Factors affecting Currency Fluctuations and Foreign Exchange Rates
      • 3.2.2.3. Impact of Foreign Exchange Rate Volatility on Market
      • 3.2.2.4. Strategies For Mitigating Foreign Exchange Risk
    • 3.2.3. Trade Policies
      • 3.2.3.1. Impact of Trade Barriers on the Market
      • 3.2.3.2. Strategies for Mitigating the Risks Associated with Trade Barriers
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

  • 5.1. Chapter Overview
  • 5.2. Overview of Targeted Protein Degradation
    • 5.2.1. Historical Evolution of Targeted Protein Degraders
  • 5.3. Targeted Protein Degrader Pathway
  • 5.4. Types of Protein Degraders
    • 5.4.1. Proteolysis Targeting Chimeras (PROTACs)
    • 5.4.2. Endosome Targeting Chimeras (ENDTACs)
    • 5.4.3. Photochemically Targeted Chimeras (PHOTACs)
    • 5.4.4. Hydrophobic Tags
    • 5.4.5. Immunomodulatory Imide Drugs (IMiDs)
    • 5.4.6. Molecular Glues
    • 5.4.7. Selective Hormone Receptor Degraders (SHRDs)
    • 5.4.8. Specific and Nongenetic inhibitor-of-apoptosis proteins (IAP)- Dependent Protein Erasers (SNIPERs)
    • 5.4.9. DUB Inhibitors
    • 5.4.10. Other Protein Degraders
  • 5.5. Targeted Therapeutic Areas
  • 5.6. Benefits and Challenges Associated with Targeted Protein Degradation
  • 5.7. Future Perspectives

6. MARKET LANDSCAPE: TARGETED PROTEIN DEGRADATION THERAPIES

  • 6.1. Chapter Overview
  • 6.2. Targeted Protein Degradation Therapies: Overall Market Landscape
    • 6.2.1. Analysis by Stage of Development
    • 6.2.2. Analysis by Type of Degrader
    • 6.2.3. Analysis by Biological Target
    • 6.2.4. Analysis by Target Enzyme
    • 6.2.5. Analysis by Target Indication
    • 6.2.6. Analysis by Therapeutic Area
  • 6.3. Targeted Protein Degradation Therapy Developers: Overall Market Landscape
    • 6.3.1. Analysis by Year of Establishment
    • 6.3.2. Analysis by Company Size
    • 6.3.3. Analysis by Location of Headquarters (Region)
    • 6.3.4. Analysis by Year of Establishment and Location of Headquarters (Region)
    • 6.3.5. Analysis by Company Size and Location of Headquarters (Region)
    • 6.3.6. Most Active Developers: Distribution by Number of Therapies and Stage of Development

7. MARKET LANDSCAPE: TARGETED PROTEIN DEGRADATION TECHNOLOGIES

  • 7.1. Chapter Overview
  • 7.2. Targeted Protein Degradation Technologies: Overall Market Landscape
    • 7.2.1. Analysis by Type of Degrader Developed
    • 7.2.2. Analysis by Protein Degradation Pathway
    • 7.2.3. Analysis by Site of Degraded Protein
    • 7.2.4. Analysis by Therapeutic Area
    • 7.2.5. Analysis by Discovery Step Supported
    • 7.2.6. Analysis by Availability of Computational Modeling Ability
    • 7.2.7. Analysis by Year of Establishment
    • 7.2.8. Analysis by Company Size
    • 7.2.9. Analysis by Location of Headquarters (Region)
    • 7.2.10. Analysis by Year of Establishment and Location of Headquarters (Region)
    • 7.2.11. Analysis by Company Size and Location of Headquarters (Region)

8. COMPANY PROFILES

  • 8.1. Chapter Overview
  • 8.2. Detailed Company Profiles of Prominent Players
    • 8.2.1. Arvinas
      • 8.2.1.1. Company Overview
      • 8.2.1.2. Financial Information
      • 8.2.1.3. Technology Portfolio
      • 8.2.1.4. Pipeline Overview
      • 8.2.1.5. Recent Developments and Future Outlook
    • 8.2.2. Bristol-Myers Squibb
      • 8.2.2.1. Company Overview
      • 8.2.2.2. Financial Information
      • 8.2.2.3. Technology Portfolio
      • 8.2.2.4. Pipeline Overview
      • 8.2.2.5. Recent Developments and Future Outlook
    • 8.2.3. C4 Therapeutics
      • 8.2.3.1. Company Overview
      • 8.2.3.2. Financial Information
      • 8.2.3.3. Technology Portfolio
      • 8.2.3.4. Pipeline Overview
      • 8.2.3.5. Recent Developments and Future Outlook
    • 8.2.4. Loxo Oncology
      • 8.2.4.1. Company Overview
      • 8.2.4.2. Pipeline Overview
      • 8.2.4.3. Recent Developments and Future Outlook
    • 8.2.5. Olema Oncology
      • 8.2.5.1. Company Overview
      • 8.2.5.2. Pipeline Overview
      • 8.2.5.3. Recent Developments and Future Outlook
    • 8.2.6. Radius Health
      • 8.2.6.1. Company Overview
      • 8.2.6.2. Financial Information
      • 8.2.6.3. Pipeline Overview
      • 8.2.6.4. Recent Developments and Future Outlook
    • 8.2.7. AstraZeneca
      • 8.2.7.1. Company Overview
      • 8.2.7.2. Financial Information
      • 8.2.7.3. Pipeline Overview
      • 8.2.7.4. Recent Developments and Future Outlook
    • 8.2.8. Roche
      • 8.2.8.1. Company Overview
      • 8.2.8.2. Financial Information
      • 8.2.8.3. Pipeline Overview
      • 8.2.8.4. Recent Developments and Future Outlook
  • 8.3. Short Profiles of Other Prominent Players
    • 8.3.1. BeiGene
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Pipeline Overview
    • 8.3.2. InnoCare Pharma
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Technology Portfolio
      • 8.3.2.3. Pipeline Overview
    • 8.3.3. Kangpu Biopharmaceuticals
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Technology Portfolio
      • 8.3.3.3. Pipeline Overview
    • 8.3.4. Kintor Pharmaceuticals
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Technology Portfolio
      • 8.3.4.3. Pipeline Overview
    • 8.3.5. Medivir
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Technology Portfolio
      • 8.3.5.3. Pipeline Overview
    • 8.3.6. Monte Rosa Therapeutics
      • 8.3.6.1. Company Overview
      • 8.3.6.2. Technology Portfolio
      • 8.3.6.3. Pipeline Overview
    • 8.3.7. Ranok Therapeutics
      • 8.3.7.1. Company Overview
      • 8.3.7.2. Technology Portfolio
      • 8.3.7.3. Pipeline Overview
    • 8.3.8. Sanofi
      • 8.3.8.1. Company Overview
      • 8.3.8.2. Pipeline Overview
    • 8.3.9. Zentalis Pharmaceuticals
      • 8.3.9.1. Company Overview
      • 8.3.9.2. Technology Portfolio
      • 8.3.9.3. Pipeline Overview
    • 8.3.10. Eisai Therapeutics
      • 8.3.10.1. Company Overview
      • 8.3.10.2. Pipeline Overview

9. CLINICAL TRIAL ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Scope and Methodology
  • 9.3. Targeted Protein Degradation: Clinical Trial Analysis
    • 9.3.1. Analysis by Trial Registration Year
    • 9.3.2. Analysis of Number of Patients Enrolled by Trial Registration Year
    • 9.3.3. Analysis by Trial Phase
    • 9.3.4. Analysis of Number of Patients Enrolled by Trial Phase
    • 9.3.5. Analysis by Trial Registration Year and Trial Phase
    • 9.3.6. Analysis by Trial Status
    • 9.3.7. Analysis by Patient Gender
    • 9.3.8. Analysis by Target Indication
    • 9.3.9. Analysis by Study Design
      • 9.3.9.1. Analysis by Type of Trial Masking
      • 9.3.9.2. Analysis by Type of Intervention Model
      • 9.3.9.3. Analysis by Trial Purpose
      • 9.3.9.4. Analysis by Design Allocation
    • 9.3.10. Most Active Sponsor / Collaborator: Analysis by Number of Registered Trials
      • 9.3.10.1. Analysis by Leading Industry Players
      • 9.3.10.2. Analysis by Leading Non-Industry Players
    • 9.3.11. Analysis by Geography
      • 9.3.11.1. Analysis of Clinical Trials by Trial Status and Geography
      • 9.3.11.2. Analysis of Patients Enrolled by Trial Status and Geography

10. GRANTS ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. Targeted Protein Degradation: Grants Analysis
    • 10.3.1. Analysis by Year of Grant Award
    • 10.3.2. Analysis by Amount Awarded
    • 10.3.3. Analysis by Funding Institute Center
    • 10.3.4. Analysis by Support Period
    • 10.3.5. Analysis by Funding Institute Center and Support Period
    • 10.3.6. Analysis by Type of Grant Application
    • 10.3.7. Analysis by Purpose of Grant Award
    • 10.3.8. Analysis by Activity Code
    • 10.3.9. Analysis by Study Section Involved
    • 10.3.10. Most Popular NIH Departments: Analysis by Number of Grants
    • 10.3.11. Prominent Program Officers: Analysis by Number of Grants
    • 10.3.12. Popular Recipient Organizations: Analysis by Number of Grants
    • 10.3.13. Popular Recipient Organizations: Analysis by Grant Amount
    • 10.3.14. Popular Recipient Organizations: Analysis by States in the US

11. PATENT ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Scope and Methodology
  • 11.3. Targeted Protein Degradation: Patents Analysis
    • 11.3.1. Analysis by Patent Publication Year
    • 11.3.2. Analysis by Patent Application Year
    • 11.3.3. Analysis of Granted Patents and Patent Applications by Publication Year
    • 11.3.4. Analysis by Patent Jurisdiction
    • 11.3.5. Analysis by CPC Symbols
    • 11.3.6. Analysis by Type of Applicant
    • 11.3.7. Leading Industry Players: Analysis by Number of Patents
    • 11.3.8. Leading Non-Industry Players: Analysis by Number of Patents
    • 11.3.9. Leading Patent Assignees: Analysis by Number of Patents
  • 11.4. Patent Benchmarking Analysis
    • 11.4.1. Analysis of Patent Characteristics (CPC Codes) by Leading Industry Players
  • 11.5. Patent Valuation
  • 11.6. Leading Patents by Number of Citations

12. PUBLICATION ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Scope and Methodology
  • 12.3. Targeted Protein Degradation: Publication Analysis
    • 12.3.1. Analysis by Year of Publication
    • 12.3.2. Analysis by Type of Publication
    • 12.3.3. Key Journals: Analysis by Number of Publications
    • 12.3.4. Key Journals: Analysis by Journal Impact Factor
    • 12.3.5. Most Active Publisher: Analysis by Number of Publications
    • 12.3.6. Most Active Copyright Holder: Analysis by Number of Publications
    • 12.3.7. Analysis by Emerging Focus Area
    • 12.3.8. Analysis by Therapeutic Area
    • 12.3.9. Analysis by Geography

13. PARTNERSHIPS AND COLLABORATIONS

  • 13.1. Chapter Overview
  • 13.2. Partnership Models
  • 13.3. Targeted Protein Degradation: Partnerships and Collaborations
    • 13.3.1. Analysis by Year of Partnership
    • 13.3.2. Analysis by Type of Partnership
    • 13.3.3. Analysis by Year and Type of Partnership
    • 13.3.4. Analysis by Type of Partner
    • 13.3.5. Analysis by Type of Degrader
    • 13.3.6. Most Active Players: Analysis by Number of Partnerships
  • 13.4. Analysis by Geography
    • 13.4.1. Local and International Agreements
    • 13.4.2. Intercontinental and Intracontinental Agreements

14. FUNDING AND INVESTMENTS

  • 14.1. Chapter Overview
  • 14.2. Funding Models
  • 14.3. Targeted Protein Degradation: Funding and Investments
    • 14.3.1. Analysis by Year of Funding
    • 14.3.2. Analysis by Amount Invested
    • 14.3.3. Analysis by Type of Funding
    • 14.3.4. Analysis by Amount Invested and Type of Funding
    • 14.3.5. Analysis of Amount Invested by Year and Type of Funding
    • 14.3.6. Analysis by Geography
    • 14.3.7. Most Active Players
      • 14.3.7.1. Analysis by Number of Funding Instances
      • 14.3.7.2. Analysis by Amount Invested
    • 14.3.8. Leading Investors: Analysis by Number of Funding Instances
  • 14.4. Concluding Remarks

15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 15.1. Chapter Overview
  • 15.2. Market Drivers
  • 15.3. Market Restraints
  • 15.4. Market Opportunities
  • 15.5. Market Challenges
  • 15.6. Conclusion

16. GLOBAL TARGETED PROTEIN DEGRADATION THERAPIES MARKET

  • 16.1. Chapter Overview
  • 16.2. Key Assumptions and Methodology
  • 16.3. Global Targeted Protein Degradation Therapies Market, Forecasted Estimates (Till 2035)
    • 16.3.1. Scenario Analysis
      • 16.3.1.1. Conservative Scenario
      • 16.3.1.2. Optimistic Scenario
  • 16.4. Key Market Segmentations

17. TARGETED PROTEIN DEGRADATION THERAPIES MARKET, BY TYPE OF DEGRADER

  • 17.1. Chapter Overview
  • 17.2. Key Assumptions and Methodology
  • 17.3. Targeted Protein Degradation Therapies Market: Distribution by Type of Degrader
    • 17.3.1. Targeted Protein Degradation Therapies Market for SERDs: Forecasted Estimates (Till 2035)
    • 17.3.2. Targeted Protein Degradation Therapies Market for PROTACs: Forecasted Estimates (Till 2035)
    • 17.3.3. Targeted Protein Degradation Therapies Market for Molecular Glues: Forecasted Estimates (Till 2035)
  • 17.4. Data Triangulation and Validation

18. TARGETED PROTEIN DEGRADATION THERAPIES MARKET, BY TARGET INDICATION

  • 18.1. Chapter Overview
  • 18.2. Key Assumptions and Methodology
  • 18.3. Targeted Protein Degradation Therapies Market: Distribution by Target Indication
    • 18.3.1. Targeted Protein Degradation Therapies Market for Breast Cancer: Forecasted Estimates (Till 2035)
    • 18.3.2. Targeted Protein Degradation Therapies Market for Multiple Myeloma: Forecasted Estimates (Till 2035)
  • 18.4. Data Triangulation and Validation

19. TARGETED PROTEIN DEGRADATION THERAPIES MARKET, BY KEY GEOGRAPHICAL REGIONS

  • 19.1. Chapter Overview
  • 19.2. Key Assumptions and Methodology
  • 19.3. Targeted Protein Degradation Therapies Market: Distribution by Key Geographical Regions
    • 19.3.1. Targeted Protein Degradation Therapies Market in North America: Forecasted Estimates (Till 2035)
      • 19.3.1.1. Targeted Protein Degradation Therapies Market in US: Forecasted Estimates (Till 2035)
      • 19.3.1.2. Targeted Protein Degradation Therapies Market in Canada: Forecasted Estimates (Till 2035)
    • 19.3.2. Targeted Protein Degradation Therapies Market in Europe: Forecasted Estimates (Till 2035)
      • 19.3.2.1. Targeted Protein Degradation Therapies Market in UK: Forecasted Estimates (Till 2035)
      • 19.3.2.2. Targeted Protein Degradation Therapies Market in Germany: Forecasted Estimates (Till 2035)
      • 19.3.2.3. Targeted Protein Degradation Therapies Market in France: Forecasted Estimates (Till 2035)
      • 19.3.2.4. Targeted Protein Degradation Therapies Market in Italy: Forecasted Estimates (Till 2035)
      • 19.3.2.5. Targeted Protein Degradation Therapies Market in Spain: Forecasted Estimates (Till 2035)
    • 19.3.3. Targeted Protein Degradation Therapies Market in Asia-Pacific: Forecasted Estimates (Till 2035)
      • 19.3.3.1. Targeted Protein Degradation Therapies Market in China: Forecasted Estimates (Till 2035)
      • 19.3.3.2. Targeted Protein Degradation Therapies Market in South Korea: Forecasted Estimates (Till 2035)
      • 19.3.3.3. Targeted Protein Degradation Therapies Market in India: Forecasted Estimates (Till 2035)
      • 19.3.3.4. Targeted Protein Degradation Therapies Market in Japan: Forecasted Estimates (Till 2035)
      • 19.3.3.5. Targeted Protein Degradation Therapies Market in Australia: Forecasted Estimates (Till 2035)
    • 19.3.4. Targeted Protein Degradation Therapies Market in Rest of the World: Forecasted Estimates (Till 2035)
      • 19.3.4.1. Targeted Protein Degradation Therapies Market in Brazil: Forecasted Estimates (Till 2035)
      • 19.3.4.2. Targeted Protein Degradation Therapies Market in Israel: Forecasted Estimates (Till 2035)
  • 19.5. Data Triangulation and Validation

20. TARGETED PROTEIN DEGRADATION THERAPIES MARKET, SALES FORECAST OF DRUGS

  • 20.1. Chapter Overview
  • 20.2. Key Assumptions and Methodology
  • 20.3. Commercialized Targeted Protein Degradation Therapies Market: Sales Forecast
    • 20.3.1. RAD1901 / Elacestrant / Orserdu Sales Forecast
  • 20.4. Phase III Targeted Protein Degradation Therapies Market: Sales Forecast
    • 20.4.1. Vepdegestrant / ARV-471 Sales Forecast
    • 20.4.2. Camizestrant / AZD9833 Sales Forecast
    • 20.4.3. CC-92480 / BMS-986348 / Mezigdomide Sales Forecast
    • 20.4.4. LY3484356 / Imlunestrant Sales Forecast
    • 20.4.5. OP-1250 / OP-1250-301 / Palazestrant Sales Forecast
  • 20.5. Data Triangulation and Validation

21. GLOBAL TARGETED PROTEIN DEGRADATION TECHNOLOGIES MARKET

  • 21.1. Chapter Overview
  • 21.2. Key Assumptions
  • 21.3. Forecast Methodology
  • 21.4. Global Targeted Protein Degradation Technologies Market, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 21.4.1. Scenario Analysis
      • 21.4.1.1. Conservative Scenario
      • 21.4.1.2. Optimistic Scenario
  • 21.5. Targeted Protein Degradation Technologies Market: Distribution by Type of Payment Model Employed
    • 21.5.1. Targeted Protein Degradation Technologies Market for Upfront Payments: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
    • 21.5.2. Targeted Protein Degradation Technologies Market for Milestone Payments: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
  • 21.6. Data Triangulation and Validation

22. EXECUTIVE INSIGHTS

  • 22.1. Chapter Overview
  • 22.2. GlycoEra
    • 22.2.1. Company Snapshot
    • 22.2.2. Interview Transcript: Ganesh Kaundinya, Chief Executive Officer and President
  • 22.3. Polyprox Therapeutics
    • 22.3.1. Company Snapshot
    • 22.3.2. Interview Transcript: Laura Itzhaki, Chief Scientific Officer and Founder
  • 22.4. Xios Therapeutics
    • 22.4.1. Company Snapshot
    • 22.4.2. Interview Transcript: Louise Bergeron, Former Chief Scientific Officer and Former Vice President, Research
  • 22.5. Mission Therapeutics
    • 22.5.1. Company Snapshot
    • 22.5.2. Interview Transcript: Paul Wallace, Former Chief Business Officer
  • 22.6. Ubiquigent
    • 22.6.1. Company Snapshot
    • 22.6.2. Interview Transcript: Jason Brown, Former Scientific and Business Development Director
  • 22.7. Almac Discovery
    • 22.7.1. Company Snapshot
    • 22.7.2. Interview Transcript: Martin Wales, Former Vice President, Business Development and Licensing and Gerald Gavory, Former Vice President, Biology
  • 22.8. University of Delaware
    • 22.8.1. Company Snapshot
    • 22.8.2. Interview Transcript: Zhihao Zhuang (Professor)
  • 22.9 Francis Crick Institute
    • 22.9.1. Company Snapshot
    • 22.9.2. Interview Transcript: Katrin Rittinger (Group Leader)
  • 22.10 Anonymous
    • 22.10.1. Interview Transcript: Chief Scientific Officer
  • 22.11 Anonymous
    • 22.11.1. Interview Transcript: Director of Oncology Research

23. CONCLUSION

24. APPENDIX 1: TABULATED DATA

25. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

26. APPENDIX 3: LIST OF FUNDING AND INVESTMENTS

List of Tables

  • Table 6.1 Targeted Protein Degradation Therapies: Information on Developer, Stage of Development and Type of Degrader
  • Table 6.2 Targeted Protein Degradation Therapies: Information on Biological Target, Target Enzyme, Target Indication and Therapeutic Area
  • Table 6.3 Targeted Protein Degradation Therapy Developers: Information on Year of Establishment, Company Size and Location of Headquarters
  • Table 7.1 Targeted Protein Degradation Technologies: Information on Type of Degrader Developed, Protein Degradation Pathway and Site of Degraded Protein
  • Table 7.2 Targeted Protein Degradation Technologies: Information on Therapeutic Area
  • Table 7.3 Targeted Protein Degradation Technologies: Information on Discovery Step Supported and CADD Ability
  • Table 7.4 Targeted Protein Degradation Technology Providers: Information on Year of Establishment, Company Size and Location of Headquarters
  • Table 8.1 List of Targeted Protein Degradation Therapy Developers Profiled
  • Table 8.2 Arvinas: Company Overview
  • Table 8.3 Arvinas: Technology Portfolio
  • Table 8.4 Arvinas: Pipeline Overview
  • Table 8.5 Arvinas: Recent Developments and Future Outlook
  • Table 8.6 Bristol-Myers Squibb: Company Overview
  • Table 8.7 Bristol-Myers Squibb: Technology Portfolio
  • Table 8.8 Bristol-Myers Squibb: Pipeline Overview
  • Table 8.9 Bristol-Myers Squibb: Recent Developments and Future Outlook
  • Table 8.10 C4 Therapeutics: Company Overview
  • Table 8.11 C4 Therapeutics: Technology Portfolio
  • Table 8.12 C4 Therapeutics: Pipeline Overview
  • Table 8.13 C4 Therapeutics: Recent Developments and Future Outlook
  • Table 8.14 Loxo Oncology: Company Overview
  • Table 8.15 Loxo Oncology: Pipeline Overview
  • Table 8.16 Olema Oncology: Company Overview
  • Table 8.17 Olema Oncology: Pipeline Overview
  • Table 8.18 Olema Oncology: Recent Developments and Future Outlook
  • Table 8.19 Radius Health: Company Overview
  • Table 8.20 Radius Health: Pipeline Overview
  • Table 8.21 Radius Health: Recent Developments and Future Outlook
  • Table 8.22 AstraZeneca: Company Overview
  • Table 8.23 AstraZeneca: Pipeline Overview
  • Table 8.24 Roche: Company Overview
  • Table 8.25 Roche: Pipeline Overview
  • Table 8.26 BeiGene: Company Overview
  • Table 8.27 BeiGene: Pipeline Overview
  • Table 8.28 InnoCare Pharma: Company Overview
  • Table 8.29 InnoCare Pharma: Technology Portfolio
  • Table 8.30 InnoCare Pharma: Pipeline Overview
  • Table 8.31 Kangpu Biopharmaceuticals: Company Overview
  • Table 8.32 Kangpu Biopharmaceuticals: Technology Portfolio
  • Table 8.33 Kangpu Biopharmaceuticals: Pipeline Overview
  • Table 8.34 Kintor Pharmaceutical: Company Overview
  • Table 8.35 Kintor Pharmaceutical: Technology Portfolio
  • Table 8.36 Kintor Pharmaceutical: Pipeline Overview
  • Table 8.37 Medivir: Company Overview
  • Table 8.38 Medivir: Technology Portfolio
  • Table 8.39 Medivir: Pipeline Overview
  • Table 8.40 Monte Rosa Therapeutics: Company Overview
  • Table 8.41 Monte Rosa Therapeutics: Technology Portfolio
  • Table 8.42 Monte Rosa Therapeutics: Pipeline Overview
  • Table 8.43 Ranok Therapeutics: Company Overview
  • Table 8.44 Ranok Therapeutics: Technology Portfolio
  • Table 8.45 Ranok Therapeutics: Pipeline Overview
  • Table 8.46 Sanofi: Company Overview
  • Table 8.47 Sanofi: Pipeline Overview
  • Table 8.48 Zentalis Pharmaceuticals: Company Overview
  • Table 8.49 Zentalis Pharmaceuticals: Technology Portfolio
  • Table 8.50 Zentalis Pharmaceuticals: Pipeline Overview
  • Table 8.51 Eisai Therapeutics: Company Overview
  • Table 8.52 Eisai Therapeutics: Pipeline Overview
  • Table 11.1 Patent Analysis: Top CPC Sections
  • Table 11.2 Patent Analysis: Top CPC Symbols
  • Table 11.3 Patent Analysis: Top CPC Codes
  • Table 11.4 Patent Analysis: Summary of Benchmarking Analysis
  • Table 11.5 Patent Analysis: Categorization based on Weighted Valuation Scores
  • Table 11.6 Patent Portfolio: List of Leading Patents (By Highest Relative Valuation)
  • Table 11.7 Patent Portfolio: List of Leading Patents (By Number of Citations)
  • Table 13.1 Targeted Protein Degradation: List of Partnerships and Collaborations
  • Table 13.2 Partnerships and Collaborations: Information on Type of Agreement (Country and Region)
  • Table 14.1 Targeted Protein Degradation: List of Funding and Investments, Since 2018
  • Table 16.1 List of Targeted Protein Degradation Therapies Forecasted
  • Table 21.1 Targeted Protein Degradation Technologies: Average Upfront Payment and Average Milestone Payment, Since 2015 (USD Million)
  • Table 21.2 Library Licensing Deal: Tranches of Milestone Payments
  • Table 22.1 GlycoEra: Company Snapshot
  • Table 22.2 Polyprox Therapeutics: Company Snapshot
  • Table 22.3 Xios Therapeutics: Company Snapshot
  • Table 22.4 Mission Therapeutics: Company Snapshot
  • Table 22.5 Ubiquigent: Company Snapshot
  • Table 22.6 Almac Discovery: Company Snapshot
  • Table 22.7 University of Delaware: Company Snapshot
  • Table 22.8 Francis Crick Institute: Company Snapshot
  • Table 22.9 Anonymous: Company Snapshot
  • Table 22.10 Anonymous: Company Snapshot
  • Table 24.1 Targeted Protein Degradation Therapies: Distribution by Stage of Development
  • Table 24.2 Targeted Protein Degradation Technologies: Distribution by Type of Degrader
  • Table 24.3 Targeted Protein Degradation Therapies: Distribution by Biological Target
  • Table 24.4 Targeted Protein Degradation Therapies: Distribution by Target Enzyme
  • Table 24.5 Targeted Protein Degradation Therapies: Distribution by Target Indication
  • Table 24.6 Targeted Protein Degradation Therapies: Distribution by Therapeutic Area
  • Table 24.7 Targeted Protein Degradation Therapy Developers: Distribution by Year of Establishment
  • Table 24.8 Targeted Protein Degradation Therapy Developers: Distribution by Company Size
  • Table 24.9 Targeted Protein Degradation Therapy Developers: Distribution by Location of Headquarters (Region)
  • Table 24.10 Targeted Protein Degradation Therapy Developers: Distribution by Year of Establishment and Location of Headquarters (Region)
  • Table 24.11 Targeted Protein Degradation Therapy Developers: Distribution by Company Size and Location of Headquarters (Region)
  • Table 24.12 Most Active Developers: Distribution by Number of Therapies and Stage of Development
  • Table 24.13 Targeted Protein Degradation Technologies: Distribution by Type of Degrader Developed
  • Table 24.14 Targeted Protein Degradation Technologies: Distribution by Protein Degradation Pathway
  • Table 24.15 Targeted Protein Degradation Technologies: Distribution by Site of Degraded Protein
  • Table 24.16 Targeted Protein Degradation Therapies: Distribution by Therapeutic Area
  • Table 24.17 Targeted Protein Degradation Therapies: Distribution by Discovery Step Supported
  • Table 24.18 Targeted Protein Degradation Technologies: Distribution by Availability of Computational Modeling Ability
  • Table 24.19 Targeted Protein Degradation Technology Providers: Distribution by Year of Establishment
  • Table 24.20 Targeted Protein Degradation Technology Providers: Distribution by Company Size
  • Table 24.21 Targeted Protein Degradation Technology Providers: Distribution by Location of Headquarters (Region)
  • Table 24.22 Targeted Protein Degradation Technology Providers: Distribution by Year of Establishment and Location of Headquarters (Region)
  • Table 24.23 Targeted Protein Degradation Technology Providers: Distribution by Company Size and Location of Headquarters (Region)
  • Table 24.24 Arvinas: Annual Revenues, Since FY 2019 (USD Million)
  • Table 24.25 Bristol-Myers Squibb: Annual Revenues, Since FY 2019 (USD Billion)
  • Table 24.26 C4 Therapeutics: Annual Revenues, Since FY 2019 (USD Million)
  • Table 24.27 Radius Health: Annual Revenues, Since FY 2019 (USD Million)
  • Table 24.28 AstraZeneca: Annual Revenues, Since FY 2019 (USD Billion)
  • Table 24.29 Roche: Annual Revenues, Since FY 2019 (CHF Billion)
  • Table 24.30 Clinical Trial Analysis: Cumulative Year-wise Trend, Since 2019
  • Table 24.31 Clinical Trial Analysis: Year-wise Trend of Patients Enrolled by Trial Registration Year, Since 2019
  • Table 24.32 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 24.33 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
  • Table 24.34 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, Since 2019
  • Table 24.35 Clinical Trial Analysis: Distribution by Trial Status
  • Table 24.36 Clinical Trial Analysis: Distribution by Patient Gender
  • Table 24.37 Clinical Trial Analysis: Distribution by Target Indication
  • Table 24.38 Clinical Trial Analysis: Distribution by Type of Trial Masking
  • Table 24.39 Clinical Trial Analysis: Distribution by Type of Intervention Model
  • Table 24.40 Clinical Trial Analysis: Distribution by Trial Purpose
  • Table 24.41 Clinical Trial Analysis: Distribution by Distribution by Design Allocation
  • Table 24.42 Leading Industry Players: Distribution by Number of Registered Trials
  • Table 24.43 Leading Non-Industry Players: Distribution by Number of Registered Trials
  • Table 24.44 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
  • Table 24.45 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
  • Table 24.46 Grants Analysis: Cumulative Year-wise Trend, Since 2019
  • Table 24.47 Grants Analysis: Cumulative Year-wise Trend of Grants by Amount Awarded (USD Million)
  • Table 24.48 Grants Analysis: Distribution by Funding Institute Center
  • Table 24.49 Grants Analysis: Distribution by Funding Institute Center and Support Period
  • Table 24.50 Grants Analysis: Distribution by Support Period
  • Table 24.51 Grants Analysis: Distribution by Type of Grant Application
  • Table 24.52 Grants Analysis: Distribution by Purpose of Grant Award
  • Table 24.53 Grants Analysis: Distribution by Activity Code (Series)
  • Table 24.54 Grants Analysis: Distribution by Activity Code
  • Table 24.55 Grants Analysis: Distribution by Study Section Involved
  • Table 24.56 Most Popular NIH Departments: Distribution by Number of Grants
  • Table 24.57 Prominent Program Officers: Distribution by Number of Grants
  • Table 24.58 Popular Recipient Organizations: Distribution by Number of Grants
  • Table 24.59 Popular Recipient Organizations: Distribution by Grant Amount (USD Million)
  • Table 24.60 Popular Recipient Organizations: Distribution by States in the US
  • Table 24.61 Patent Analysis: Distribution by Type of Patent
  • Table 24.62 Patent Analysis: Distribution by Patent Publication Year, Since 2019
  • Table 24.63 Patent Analysis: Distribution by Patent Application Year, Since Pre-2019
  • Table 24.64 Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications, Since 2019
  • Table 24.65 Patent Analysis: Distribution by Patent Jurisdiction
  • Table 24.66 Patent Analysis: Cumulative Year-wise Trend by Type of Applicant
  • Table 24.67 Leading Industry Players: Distribution by Number of Patents
  • Table 24.68 Leading Non-Industry Players: Distribution by Number of Patents
  • Table 24.69 Leading Patent Assignees: Distribution by Number of Patents
  • Table 24.70 Patent Analysis: Distribution by Patent Age
  • Table 24.71 Patent Analysis: Patent Valuation
  • Table 24.72 Publication Analysis: Distribution by Year of Publication, Since 2019
  • Table 24.73 Publication Analysis: Distribution by Type of Publication
  • Table 24.74 Key Journals: Distribution by Number of Publications
  • Table 24.75 Key Journals: Distribution by Journal Impact Factor
  • Table 24.76 Most Active Publisher: Distribution by Number of Publications
  • Table 24.77 Most Active Copyright Holder: Distribution by Number of Publications
  • Table 24.78 Publication Analysis: Emerging Focus Area
  • Table 24.79 Publication Analysis: Distribution by Therapeutic Area
  • Table 24.80 Publication Analysis: Distribution by Geography
  • Table 24.81 Partnerships and Collaborations: Cumulative Year-wise Trend, Since Pre-2016
  • Table 24.82 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 24.83 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since Pre-2016
  • Table 24.84 Partnerships and Collaborations: Distribution by Type of Partner
  • Table 24.85 Partnerships and Collaborations: Distribution by Type of Degrader
  • Table 24.86 Most Active Players: Distribution by Number of Partnerships
  • Table 24.87 Partnerships and Collaborations: Local and International Agreements
  • Table 24.88 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Table 24.89 Funding and Investment Analysis: Cumulative Year-wise Trend, Since 2014
  • Table 24.90 Funding and Investment Analysis: Distribution by Amount Invested, Since 2014 (USD Million)
  • Table 24.91 Funding and Investment Analysis: Distribution of Instances by Type of Funding, Since 2018
  • Table 24.92 Funding and Investments: Distribution by Type of Funding and Amount Invested (USD Million)
  • Table 24.93 Year wise Distribution of Amount Invested by Type of Funding, Since 2018
  • Table 24.94 Funding and Investments: Distribution by Geography (Region)
  • Table 24.95 Funding and Investments: Distribution by Geography (Country)
  • Table 24.96 Most Active Players: Distribution by Number of Funding Instances
  • Table 24.97 Most Active Players: Distribution by Amount Raised (USD Million)
  • Table 24.98 Key Investors: Distribution by Number of Funding Instances
  • Table 24.99 Funding and Investments Summary, Since 2018 (USD Million)
  • Table 24.100 Global Targeted Protein Degradation Therapies Market, Conservative, Base and Optimistic Scenario, Till 2035 (USD Million)
  • Table 24.101 Targeted Protein Degradation Therapies Market: Distribution by Type of Degrader
  • Table 24.102 Targeted Protein Degradation Therapies Market for SERDs: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.103 Targeted Protein Degradation Therapies Market for PROTACs: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.104 Targeted Protein Degradation Therapies Market for Molecular Glues: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.105 Targeted Protein Degradation Therapies Market: Distribution by Target Indication
  • Table 24.106 Targeted Protein Degradation Therapies Market for Breast Cancer: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.107 Targeted Protein Degradation Therapies Market for Multiple Myeloma: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.108 Targeted Protein Degradation Therapies Market: Distribution by Key Geographical Regions (USD Million)
  • Table 24.109 Targeted Protein Degradation Therapies Market in North America: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.110 Targeted Protein Degradation Therapies Market in the US: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.111 Targeted Protein Degradation Therapies Market in Canada: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.112 Targeted Protein Degradation Therapies Market in Europe: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.113 Targeted Protein Degradation Therapies Market in the UK: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.114 Targeted Protein Degradation Therapies Market in Germany: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.115 Targeted Protein Degradation Therapies Market in France: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.116 Targeted Protein Degradation Therapies Market in Spain: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.117 Targeted Protein Degradation Therapies Market in Italy: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.118 Targeted Protein Degradation Therapies Market in Asia-Pacific: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.119 Targeted Protein Degradation Therapies Market in China: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.120 Targeted Protein Degradation Therapies Market in South Korea: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.121 Targeted Protein Degradation Therapies Market in India: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.122 Targeted Protein Degradation Therapies Market in Japan: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.123 Targeted Protein Degradation Therapies Market in Australia: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.124 Targeted Protein Degradation Therapies Market in Rest of the World: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.125 Targeted Protein Degradation Therapies Market in Brazil: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.126 Targeted Protein Degradation Therapies Market in Israel: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.127 Targeted Protein Degradation Therapies Market: RAD1901 / Elacestrant / Orserdu Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.128 Targeted Protein Degradation Therapies Market: Vepedegestrant / ARV-471 Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.129 Targeted Protein Degradation Therapies Market: OP-1250 / OP-1250-301 / Palazestrant Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.130 Targeted Protein Degradation Therapies Market: LY3484356 / Imlunestrant Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.131 Targeted Protein Degradation Therapies Market: CC-92480 / BMS-986348 / Mezigdomide Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.132 Targeted Protein Degradation Therapies Market: Camizestrant / AZD9833 Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.133 Global Targeted Protein Degradation Technologies Market, Historical Trends (Since 2018), Base Scenario (USD Million)
  • Table 24.134 Global Targeted Protein Degradation Technologies Market, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.135 Targeted Protein Degradation Technologies Market: Distribution by Type of Payment Model Employed (USD Million)
  • Table 24.136 Targeted Protein Degradation Technologies Market for Upfront Payments, Historical Trends Since 2018, Base Scenario (USD Million)
  • Table 24.137 Targeted Protein Degradation Technologies Market for Upfront Payments, Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 24.138 Targeted Protein Degradation Technologies Market for Milestone Payments, Historical Trends, Since 2018, Base Scenario (USD Million)
  • Table 24.139 Targeted Protein Degradation Technologies Market for Milestone Payments, Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenario (USD Million)
  • Table 26.1 Targeted Protein Degradation: List of Funding and Investments, Since 2014

List of Figures

  • Figure 2.1 Research Methodology: Project Methodology
  • Figure 2.2 Research Methodology: Forecast Methodology
  • Figure 2.3 Research Methodology: Robust Quality Control
  • Figure 2.4 Research Methodology: Key Market Segmentations
  • Figure 3.1 Lessons Learnt from Past Recessions
  • Figure 4.1 Executive Summary: Targeted Protein Degradation Therapies Market Landscape
  • Figure 4.2 Executive Summary: Targeted Protein Degradation Technologies Market Landscape
  • Figure 4.3 Executive Summary: Clinical Trial Analysis
  • Figure 4.4 Executive Summary: Grants Analysis
  • Figure 4.5 Executive Summary: Patent Analysis
  • Figure 4.6 Executive Summary: Publication Analysis
  • Figure 4.7 Executive Summary: Partnerships and Collaborations
  • Figure 4.8 Executive Summary: Funding and Investments
  • Figure 4.9 Executive Summary: Therapies Market Forecast and Opportunity Analysis
  • Figure 4.10 Executive Summary: Technologies Market Forecast and Opportunity Analysis
  • Figure 5.1 Timeline of Induced Protein Degradation Field
  • Figure 5.2 Ubiquitin-Proteasome System Pathway
  • Figure 5.3 Types of Protein Degraders
  • Figure 5.4 Mechanism of Action of PROTAC
  • Figure 5.5 Advantages of PROTACs
  • Figure 5.6 Mechanism of Action of ENDTAC
  • Figure 5.7 Mechanism of Action of PHOTAC
  • Figure 5.8 Mechanism of Action of Hydrophobic Tag
  • Figure 5.9 Mechanism of Action of IMiD
  • Figure 5.10 Mechanism of Action of Molecular Glue
  • Figure 5.11 Mechanism of Action of SERD
  • Figure 5.12 Mechanism of Action of SNIPER
  • Figure 5.13 Protein Degradation: Targeted Therapeutic Areas
  • Figure 6.1 Targeted Protein Degradation Therapies: Distribution by Stage of Development
  • Figure 6.2 Targeted Protein Degradation Technologies: Distribution by Type of Degrader
  • Figure 6.3 Targeted Protein Degradation Therapies: Distribution by Biological Target
  • Figure 6.4 Targeted Protein Degradation Therapies: Distribution by Target Enzyme
  • Figure 6.5 Targeted Protein Degradation Therapies: Distribution by Target Indication
  • Figure 6.6 Targeted Protein Degradation Therapies: Distribution by Therapeutic Area
  • Figure 6.7 Targeted Protein Degradation Therapy Developers: Distribution by Year of Establishment
  • Figure 6.8 Targeted Protein Degradation Therapy Developers: Distribution by Company Size
  • Figure 6.9 Targeted Protein Degradation Therapy Developers: Distribution by Location of Headquarters (Region)
  • Figure 6.10 Targeted Protein Degradation Therapy Developers: Distribution by Year of Establishment and Location of Headquarters (Region)
  • Figure 6.11 Targeted Protein Degradation Therapy Developers: Distribution by Company Size and Location of Headquarters (Region)
  • Figure 6.12 Most Active Developers: Distribution by Number of Therapies and Stage of Development
  • Figure 7.1 Targeted Protein Degradation Technologies: Distribution by Type of Degrader Developed
  • Figure 7.2 Targeted Protein Degradation Technologies: Distribution by Protein Degradation Pathway
  • Figure 7.3 Targeted Protein Degradation Technologies: Distribution by Site of Degraded Protein
  • Figure 7.4 Targeted Protein Degradation Technologies: Distribution by Therapeutic Area
  • Figure 7.5 Targeted Protein Degradation Technologies: Distribution by Discovery Step Supported
  • Figure 7.6 Targeted Protein Degradation Technologies: Distribution by Availability of Computational Modeling Ability
  • Figure 7.7 Targeted Protein Degradation Technology Providers: Distribution by Year of Establishment
  • Figure 7.8 Targeted Protein Degradation Technology Providers: Distribution by Company Size
  • Figure 7.9 Targeted Protein Degradation Technology Providers: Distribution by Location of Headquarters (Region)
  • Figure 7.10 Targeted Protein Degradation Technology Providers: Distribution by Year of Establishment and Location of Headquarters (Region)
  • Figure 7.11 Targeted Protein Degradation Technology Providers: Distribution by Company Size and Location of Headquarters (Region)
  • Figure 8.1 Arvinas: Annual Revenues, Since FY 2019 (USD Million)
  • Figure 8.2 Bristol-Myers Squibb: Annual Revenues, Since FY 2019 (USD Billion)
  • Figure 8.3 C4 Therapeutics: Annual Revenues, Since FY 2019 (USD Million)
  • Figure 8.4 Radius Health: Annual Revenues, Since FY 2019 (USD Million)
  • Figure 8.5 AstraZeneca: Annual Revenues, Since FY 2019 (USD Billion)
  • Figure 8.6 Roche: Annual Revenues, Since FY 2019 (CHF Billion)
  • Figure 9.1 Clinical Trial Analysis: Cumulative Year-wise Trend, Since 2019
  • Figure 9.2 Clinical Trial Analysis: Year-wise Trend of Patients Enrolled by Trial Registration Year, Since 2019
  • Figure 9.3 Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 9.4 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
  • Figure 9.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, Since 2019
  • Figure 9.6 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 9.7 Clinical Trial Analysis: Distribution by Patient Gender
  • Figure 9.8 Clinical Trial Analysis: Distribution by Target Indication
  • Figure 9.9 Clinical Trial Analysis: Distribution by Type of Trial Masking
  • Figure 9.10 Clinical Trial Analysis: Distribution by Type of Intervention Model
  • Figure 9.11 Clinical Trial Analysis: Distribution by Trial Purpose
  • Figure 9.12 Clinical Trial Analysis: Distribution by Design Allocation
  • Figure 9.13 Leading Industry Players: Distribution by Number of Registered Trials
  • Figure 9.14 Leading Non-Industry Players: Distribution by Number of Registered Trials
  • Figure 9.15 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
  • Figure 9.16 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
  • Figure 10.1 Grants Analysis: Cumulative Year-wise Trend, Since 2019
  • Figure 10.2 Grants Analysis: Cumulative Year-wise Trend of Grants by Amount Awarded (USD Million)
  • Figure 10.3 Grants Analysis: Distribution by Funding Institute Center
  • Figure 10.4 Grants Analysis: Distribution by Support Period
  • Figure 10.5 Grants Analysis: Distribution by Funding Institute Center and Support Period
  • Figure 10.6 Grants Analysis: Distribution by Type of Grant Application
  • Figure 10.7 Grants Analysis: Distribution by Purpose of Grant Award
  • Figure 10.8 Grants Analysis: Distribution by Activity Code (Series)
  • Figure 10.9 Grants Analysis: Distribution by Activity Code
  • Figure 10.10 Grants Analysis: Distribution by Study Section Involved
  • Figure 10.11 Most Popular NIH Departments: Distribution by Number of Grants
  • Figure 10.12 Prominent Program Officers: Distribution by Number of Grants
  • Figure 10.13 Popular Recipient Organizations: Distribution by Number of Grants
  • Figure 10.14 Popular Recipient Organizations: Distribution by Grant Amount (USD Million)
  • Figure 10.15 Popular Recipient Organizations: Distribution by States in the US
  • Figure 11.1 Patent Analysis: Distribution by Type of Patent
  • Figure 11.2 Patent Analysis: Distribution by Patent Publication Year, Since 2019
  • Figure 11.3 Patent Analysis: Distribution by Patent Application Year, Since Pre-2019
  • Figure 11.4 Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications, Since 2019
  • Figure 11.5 Patent Analysis: Distribution by Patent Jurisdiction
  • Figure 11.6 Patent Analysis: Distribution by CPC Symbols
  • Figure 11.7 Patent Analysis: Cumulative Year-wise Trend by Type of Applicant
  • Figure 11.8 Leading Industry Players: Distribution by Number of Patents
  • Figure 11.9 Leading Non-Industry Players: Distribution by Number of Patents
  • Figure 11.10 Leading Patent Assignees: Distribution by Number of Patents
  • Figure 11.11 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
  • Figure 11.12 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
  • Figure 11.13 Patent Analysis: Distribution by Patent Age
  • Figure 11.14 Targeted Protein Degradation: Patent Valuation
  • Figure 12.1 Publication Analysis: Distribution by Year of Publication, Since 2019
  • Figure 12.2 Publication Analysis: Distribution by Type of Publication
  • Figure 12.3 Key Journals: Distribution by Number of Publications
  • Figure 12.4 Key Journals: Distribution by Journal Impact Factor
  • Figure 12.5 Most Active Publisher: Distribution by Number of Publications
  • Figure 12.6 Most Active Copyright Holder: Distribution by Number of Publications
  • Figure 12.7 Publication Analysis: Emerging Focus Area
  • Figure 12.8 Publication Analysis: Distribution by Therapeutic Area
  • Figure 12.9 Publication Analysis: Distribution by Geography
  • Figure 13.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since Pre-2016
  • Figure 13.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 13.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since Pre-2016
  • Figure 13.4 Partnerships and Collaborations: Distribution by Type of Partner
  • Figure 13.5 Partnerships and Collaborations: Distribution by Type of Degrader
  • Figure 13.6 Most Active Players: Distribution by Number of Partnerships
  • Figure 13.7 Partnership and Collaborations: Local and International Agreements
  • Figure 13.8 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Figure 14.1 Funding and Investment Analysis: Cumulative Year-wise Trend, Since 2014
  • Figure 14.2 Funding and Investment Analysis: Distribution by Amount Invested, Since 2014 (USD Million)
  • Figure 14.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding, Since 2018
  • Figure 14.4 Funding and Investment Analysis: Distribution by Amount Invested and Type of Funding (USD Million)
  • Figure 14.5 Year-wise Distribution of Amount Invested by Type of Funding, Since 2018
  • Figure 14.6 Funding and Investment Analysis: Distribution by Geography (Region)
  • Figure 14.7 Funding and Investment Analysis: Distribution by Geography (Country)
  • Figure 14.8 Most Active Players: Distribution by Number of Funding Instances
  • Figure 14.9 Most Active Players: Distribution by Amount Invested (USD Million)
  • Figure 14.10 Leading Investors: Distribution by Number of Funding Instances
  • Figure 14.11 Funding and Investment Summary, Since 2018 (USD Million)
  • Figure 15.1 Targeted Protein Degradation: Market Drivers
  • Figure 15.2 Targeted Protein Degradation: Market Restraints
  • Figure 15.3 Targeted Protein Degradation: Market Opportunities
  • Figure 15.4 Targeted Protein Degradation: Market Challenges
  • Figure 16.1 Global Targeted Protein Degradation Therapies Market, Till 2035 (USD Million)
  • Figure 16.2 Global Targeted Protein Degradation Therapies Market, Till 2035: Conservative Scenario (USD Million)
  • Figure 16.3 Global Targeted Protein Degradation Therapies Market, Till 2035: Optimistic Scenario (USD Million)
  • Figure 17.1 Targeted Protein Degradation Therapies Market: Distribution by Type of Degrader
  • Figure 17.2 Targeted Protein Degradation Therapies Market for SERDs: Forecasted Estimates (Till 2035) (USD Million)
  • Figure 17.3 Targeted Protein Degradation Therapies Market for PROTACs: Forecasted Estimates (Till 2035) (USD Million)
  • Figure 17.4 Targeted Protein Degradation Therapies Market for Molecular Glues: Forecasted Estimates (Till 2035) (USD Million)
  • Figure 18.1 Targeted Protein Degradation Therapies Market: Distribution by Target Indication
  • Figure 18.2 Targeted Protein Degradation Therapies Market for Breast Cancer: Forecasted Estimates (Till 2035) (USD Million)
  • Figure 18.3 Targeted Protein Degradation Therapies Market for Multiple Myeloma: Forecasted Estimates (Till 2035) (USD Million)
  • Figure 19.1 Targeted Protein Degradation Therapies Market: Distribution by Key Geographical Regions (USD Million)
  • Figure 19.2 Targeted Protein Degradation Therapies Market in North America: Forecasted Estimates (Till 2035) (USD Million)
  • Figure 19.3 Targeted Protein Degradation Therapies Market in the US: Forecasted Estimates (Till 2035) (USD Million)
  • Figure 19.4 Targeted Protein Degradation Therapies Market in Canada: Forecasted Estimates (Till 2035) (USD Million)
  • Figure 19.5 Targeted Protein Degradation Therapies Market in Europe: Forecasted Estimates (Till 2035) (USD Million)
  • Figure 19.6 Targeted Protein Degradation Therapies Market in the UK: Forecasted Estimates (Till 2035) (USD Million)
  • Figure 19.7 Targeted Protein Degradation Therapies Market in Germany: Forecasted Estimates (Till 2035) (USD Million)
  • Figure 19.8 Targeted Protein Degradation Therapies Market in France: Forecasted Estimates (Till 2035) (USD Million)
  • Figure 19.9 Targeted Protein Degradation Therapies Market in Spain: Forecasted Estimates (Till 2035) (USD Million)
  • Figure 19.10 Targeted Protein Degradation Therapies Market in Italy: Forecasted Estimates (Till 2035) (USD Million)
  • Figure 19.11 Targeted Protein Degradation Therapies Market in Asia-Pacific: Forecasted Estimates (Till 2035) (USD Million)
  • Figure 19.12 Targeted Protein Degradation Therapies Market in China: Forecasted Estimates (Till 2035) (USD Million)
  • Figure 19.13 Targeted Protein Degradation Therapies Market in South Korea: Forecasted Estimates (Till 2035) (USD Million)
  • Figure 19.14 Targeted Protein Degradation Therapies Market in India: Forecasted Estimates (Till 2035) (USD Million)
  • Figure 19.15 Targeted Protein Degradation Therapies Market in Japan: Forecasted Estimates (Till 2035) (USD Million)
  • Figure 19.16 Targeted Protein Degradation Therapies Market in Australia: Forecasted Estimates (Till 2035) (USD Million)
  • Figure 19.17 Targeted Protein Degradation Therapies Market in Rest of the World: Forecasted Estimates (Till 2035) (USD Million)
  • Figure 19.18 Targeted Protein Degradation Therapies Market in Brazil: Forecasted Estimates (Till 2035) (USD Million)
  • Figure 19.19 Targeted Protein Degradation Therapies Market in Israel: Forecasted Estimates (Till 2035) (USD Million)
  • Figure 20.1 Targeted Protein Degradation Therapies Market: RAD1901 / Elacestrant / Orserdu Sales Forecast, Till 2035 (USD Million)
  • Figure 20.2 Targeted Protein Degradation Therapies Market: Vepedegestrant / ARV-471 Sales Forecast, Till 2035 (USD Million)
  • Figure 20.3 Targeted Protein Degradation Therapies Market: OP-1250 / OP-1250-301 / Palazestrant Sales Forecast, Till 2035 (USD Million)
  • Figure 20.4 Targeted Protein Degradation Therapies Market: LY3484356 / Imlunestrant Sales Forecast, Till 2035 (USD Million)
  • Figure 20.5 Targeted Protein Degradation Therapies Market: CC-92480 / BMS-986348 / Mezigdomide Sales Forecast, Till 2035 (USD Million)
  • Figure 20.6 Targeted Protein Degradation Therapies Market: Camizestrant / AZD9833 Sales Forecast, Till 2035 (USD Million)
  • Figure 21.1 Licensing Agreements: Distribution of Financial Components
  • Figure 21.2 Licensing Agreements: Illustrative Scenario based Opportunity Estimation
  • Figure 21.3 Global Targeted Protein Degradation Technologies Market, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 21.4 Global Targeted Protein Degradation Technologies Market, Till 2035: Conservative Scenario (USD Million)
  • Figure 21.5 Global Targeted Protein Degradation Technologies Market, Till 2035: Optimistic Scenario (USD Million)
  • Figure 21.6 Targeted Protein Degradation Technologies Market: Distribution by Type of Payment Model Employed
  • Figure 21.7 Targeted Protein Degradation Technologies Market for Upfront Payments, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 21.8 Targeted Protein Degradation Technologies Market for Milestone Payments, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Million)
  • Figure 23.1 Conclusion: Targeted Protein Degradation Therapies Market Landscape
  • Figure 23.2 Conclusion: Targeted Protein Degradation Technologies Market Landscape
  • Figure 23.3 Conclusion: Clinical Trial Analysis
  • Figure 23.4 Conclusion: Grants Analysis
  • Figure 23.5 Conclusion: Patent Analysis
  • Figure 23.6 Conclusion: Publication Analysis
  • Figure 23.7 Conclusion: Partnerships and Collaborations
  • Figure 23.8 Conclusion: Funding and Investments
  • Figure 23.9 Conclusion: Therapies Market Forecast and Opportunity Analysis
  • Figure 23.10 Conclusion: Technologies Market Forecast and Opportunity Analysis